Abstract
Between October 1995 and October 1998, 24 children aged 9 months to 17 years (median 11 years) underwent cytokine-mobilized allogeneic peripheral blood stem cell (PBSC) transplantation for treatment of hematological disorders. All of the transplants were the first allogeneic transplant for the recipient. Twenty patients were transplanted for hematological malignancies (ALL = 8, AML = 6, CML = 4, MDS = 2) and four patients were transplanted for non-malignant disease (thalassemia major = 2, Wiskott–Aldrich syndrome = 1, Kostmann's syndrome = 1). Nineteen donors were HLA-identical siblings, four were HLA-matched or single antigen mismatched parents, and one was a syngeneic transplant. Donors aged 8 to 38 years (median 15 years, 14 donors v18 years) received g-csf 10 μg/kg/day subcutaneously beginning 4 days before pbsc collection and were submitted to one to three leukapheresis collections. the median cd34+ cell yield was 7.8 × 106 cells/kg recipient body weight. all patients achieved an anc >0.5 × 109/l after a median of 13 days (range 10–21). Twenty-three patients eventually achieved platelet transfusion independence. One patient died on day 63 without ever achieving platelet transfusion independence. Four patients received platelet transfusions to maintain a platelet count well above 20 × 109/l due to bleeding complications. Of the 19 evaluable patients, the median time to a non-transfused platelet count of 20 × 109/l was 12 days (range 0–44). Ten of 23 at-risk patients developed acute GVHD grades II to IV, with grades III to IV in four patients. Twelve of 19 patients followed for at least 100 days have developed chronic GVHD (extensive = 2, limited = 10) with an actuarial risk of chronic GVHD of 75% at 1 year. The Kaplan–Meier estimate of event-free survival is 65% at 2 years. Four patients died (GVHD = 3, VOD = 1), three patients relapsed, and one patient with thalassemia major had a late graft failure with autologous recovery. Based upon our experience, allogeneic PBSCT is safe for both pediatric donors and recipients and engraftment of neutrophils and platelets is rapid. Bone Marrow Transplantation (2000) 25, 13–18.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Henon PhR, Liang H, Beck-Wirth G et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants Bone Marrow Transplant 1992 9: 285–291
To LB, Roberts MM, Haylock DN et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants Bone Marrow Transplant 1992 9: 277–284
Huan S, Hester J, Spitzer G et al. Influence of mobilized peri-pheral blood cells on the hematopoietic recovery of autologous marrow and recombinant human granulocyte–macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin Blood 1992 79: 3388–3393
Leibundgut K, Hirt A, Ridolfi Lüthy A et al. Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review Eur J Pediatr 1993 152: 546–554
Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peri-pheral blood of normal donors by granulocyte–macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation Blood 1995 85: 275–282
Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advancedhematologic malignancies: a retrospective comparison withmarrow transplantation Blood 1996 88: 2794–2800
Champlin R, Schmitz N, Horowitz M . Allogeneic blood stem cell (BSC) vs. bone marrow transplantation (BMT): improved leukemia-free survival in high risk but not low risk patients Blood 1998 92: (Suppl.1) 2710a
Lickliter JD, DeFor T, Wagner JE et al. Matched-pair analysis of peripheral blood stem cells compared to marrow for allo-geneic transplantation Blood 1998 92: (Suppl.1) 561a
Ottinger HD, Beelen DW, Sheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow Blood 1996 88: 2775–2779
Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation New Engl J Med 1975 292: 895–902
Minero R, Busca A, Bonetti F et al. Allogeneic transplantation of peripheral blood progenitor cells in children: experience of two pediatric centers Bone Marrow Transplant 1998 22: (Suppl.5) S33–S36
Diaz MA, Alegre A, Villa M et al. Allogeneic peripheral blood progenitor cell (PBPC) transplantation in children with haematological malignancies Br J Haematol 1997 96: 161–164
Schriber JR, Chao NJ, Long GD et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation Blood 1994 84: 1680–1684
Ringden O, Horowitz MM, Sondel P et al . Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993 81: 1094–1101
Urbano-Ispizua A, Garcia-Conde J, Brunet S et al. High incidence of chronic graft-versus-host disease after allogeneic peri-pheral blood progenitor cell transplantation. The Spanish Group of allo-PBPCT Haematologica 1997 82: 683–689
Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease Blood 1997 90: 4705–4709
Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 1990 75: 555–562
Acknowledgements
The authors gratefully acknowledge the excellent technical expertise and clinical care provided by the apheresis and BMT unit staffs at our respective hospitals.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levine, J., Wiley, J., Kletzel, M. et al. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. Bone Marrow Transplant 25, 13–18 (2000). https://doi.org/10.1038/sj.bmt.1702081
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702081
Keywords
This article is cited by
-
G-CSF-primed BM for allogeneic SCT: revisited
Bone Marrow Transplantation (2015)
-
Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias
Bone Marrow Transplantation (2006)
-
Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996–2003
Bone Marrow Transplantation (2005)
-
Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH)
Bone Marrow Transplantation (2005)
-
Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients
Bone Marrow Transplantation (2004)